Jammu Journal

DelveInsight Business Research LLP

(United States, Nevada, Las Vegas), DelveInsight’s “Sialorrhea – Pipeline Insight, 2023” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Sialorrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Sialorrhea Pipeline Report

• Over 3+ companies and 3+ pipeline drugs in Sialorrhea are in various stages of development, and their anticipated acceptance in the Sialorrhea market would significantly increase market revenue. 

• Leading Sialorrhea companies developing novel drug candidates to improve the Sialorrhea treatment landscape include Nobelpharma Aytu BioPharma, NeuroHealing Pharmaceuticals, Orient Pharma, and many others.

• Promising Sialorrhea pipeline therapies in various stages of development include NT0502 and many others.

 Sialorrhea Overview

Sialorrhea, drooling, or excessive salivation is a common problem in neurologically impaired children and in adults who have Parkinson’s disease or have had a stroke. It is most commonly caused by poor oral and facial muscle control. Sialorrhea can lead to significant physical and psychosocial complications, including perioral chapping, dehydration, infection, foul odor, stigmatization, and increased dependency and level of care, all of which can create an additional burden for these medically complicated patients. Sialorrhea usually is caused by neuromuscular dysfunction, hypersecretion, sensory dysfunction, or anatomic (motor) dysfunction. The most common cause is neuromuscular dysfunction. Anterior sialorrhea is diagnosed by the observation of excessive drooling. Posterior sialorrhea can be suggested by the history of choking and repeated pneumonia. Treatment for Sialorrhea range from conservative (i.e., observation, postural changes, biofeedback) to more aggressive measures such as medication, radiation, and surgical therapy.

Sialorrhea Pipeline Analysis: Drug Profile

NT0502: Aytu BioPharma

NT0502 (N-desethyloxybutynin) is an oral, once- or twice-daily potential treatment to reduce chronic sialorrhea in patients with neurological and other conditions associated with drooling and excessive salivation. In December 2020, Aytu BioScience and Neos Therapeutics announced that they have entered into a definitive merger agreement according to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction. In March 2022, Aytu BioScience announced the close of the merger with Neos Therapeutics. NT0502 is currently in Phase 1 clinical development for the treatment of chronic sialorrhea.

Discover more about the emerging Sialorrhea  drugs @ Sialorrhea Disease Treatment Drugs

Sialorrhea Pipeline Therapies and Key Companies

• NT0502: Aytu BioPharma

And many others 

Sialorrhea Pipeline Therapeutics Assessment

This segment of the report provides insights about the different Sialorrhea drugs segregated based on the following parameters that define the scope of the report, such as:

Major Players in Sialorrhea

There are approx. 3+ key companies developing therapies for Sialorrhea. The companies which have their Sialorrhea drug candidates in the most advanced stage, i.e. phase III include Corcept Therapeutics.

Phases

DelveInsight’s Report covers around 8+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Route of Administration

The Sialorrhea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

• Molecule Type

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

• Product Type

Scope of the Sialorrhea Pipeline Report 

• Coverage: Global 

• Key Sialorrhea Companies: Nobelpharma Aytu BioPharma, NeuroHealing Pharmaceuticals, Orient Pharma, and many others.

• Key Sialorrhea Pipeline Therapies:  NT0502 and many others.

Find out more about the Sialorrhea  treatment options in development@ Sialorrhea Clinical Trials

Table of Contents

1. Sialorrhea Introduction

2. Sialorrhea Executive Summary

3. Sialorrhea Overview

4. Sialorrhea Pipeline Therapeutics

5. Sialorrhea Late-Stage Products (Phase III)

6. Sialorrhea Mid-Stage Products (Phase  II)

7. Sialorrhea Early Stage Products (Phase  I/II)

8. Sialorrhea Preclinical Stage Products

9. Sialorrhea Discovery Stage Products

10. Sialorrhea Therapeutic Assessment

11. Sialorrhea Inactive Products

12. SialorrheaCollaborations Assessment- Licensing / Partnering / Funding

13. Sialorrhea Unmet Needs

14. Sialorrhea Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services